HTG and MD Anderson Cancer Center Enter Into a Sponsored Research Agreement to Investigate New Molecular Diagnostics for Lung Cancer Using HTG's Next-Generation Sequencing Solution for Gene Expression
HTG expects the project will provide critical information for selection of novel therapies and better predict outcomes in lung cancer patients than currently accepted genomic analysis alone.
"We are thrilled to partner with MD Anderson in this Sponsored Research Agreement to investigate new assays to better diagnose and treat patients diagnosed with lung cancer," stated TJ Johnson, HTG Molecular Chief Executive Officer.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected benefits from the sponsored research agreement and the capabilities of our technology. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks inherent in molecular profiling research and development activities. These and other factors are described in greater detail in our final prospectus for our initial public offering, filed with the
Westwicke Partners Jamar IsmailPhone: 415-513-1282 Email: email@example.com TJ Johnson President / CEO HTG Molecular DiagnosticsPhone: 520-547-2827 x2130 Email: firstname.lastname@example.org